Related Experiment Video
Updated: Oct 15, 2025
06:59
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
125
[stent thrombosis : A won battle ? (data from the France PCI registry)]
G Rangé1, R Hakim1, C Saint Etienne2
1Hôpitaux de Chartres, Service de Cardiologie, 4 rue Claude Bernard 28630 Le Coudray.
Annales De Cardiologie Et D'Angeiologie
|October 23, 2021
Summary
The incidence of stent thrombosis (ST) decreased since 2014 but remains high, with identified risk factors. Despite advancements, ST continues to have a significant impact on patient mortality.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Clinical Research
Background:
- Stent thrombosis (ST) remains a serious complication following coronary angioplasty.
- Understanding the incidence, risk factors, and outcomes of ST is crucial for improving patient care.
Purpose of the Study:
- To assess the 1-year incidence, identify risk factors, and evaluate the prognosis of definite stent thrombosis (ST).
- To analyze trends in ST rates within a large, multicenter prospective registry in France.
Main Methods:
- A prospective registry included 35,435 patients undergoing coronary angioplasty with stent implantation from 2014 to 2019.
- Patients were categorized into ST and control groups to compare outcomes and risk factors.
Main Results:
- The overall 1-year ST incidence was 0.72%, decreasing in acute coronary syndromes but not chronic ones.
- Identified risk factors for ST include younger age, diabetes, renal failure, previous angioplasty, LV dysfunction, longer stent length, and lower pre-procedure TIMI flow.
- 1-year mortality was significantly higher in the ST group (19.14%) compared to the control group (5.82%).
Conclusions:
- While the incidence of ST has decreased, it has plateaued, indicating a persistent challenge.
- Risk factors for ST are well-defined, but its high associated mortality necessitates continued efforts in prevention and management.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
56
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
56
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
71
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
71
01:30Acute Coronary Syndrome III: Diagnostic Studies
44
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
44
01:27Coronary Artery Disease V: Interprofessional Care
68
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
68
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
748
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
748
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
68
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
68